TP53 and acute myeloid leukemia: Additionally, a phase 2 trial (NCT03931291) was conducted to investigate the efficacy and safety of APR-246 in combination with azacitidine for p53-mutated MDS or AML patients as post-hematopoietic stem-cell transplantation (HCT) maintenance therapy [26].